Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Anti-CTLA-4 antibodies are human monoclonal antibodies previously studied in the treatment of metastatic melanoma (MM). CTLA-4 is an inhibitory receptor on cytotoxic T cells, blockade of which will activate T cells allowing them to attack malignant cells. Normal host cells may also be affected, and immune-mediated enterocolitis can occur. This is a prospective observational study on the use of corticosteroids and infliximab in the treatment of patients with immune-mediated colitis secondary to anti-CTLA-4 antibody treatment of MM. Five patients presented with colitis after medication administration. Patients were treated with high-dose corticosteroids for 1 week, but diarrhea did not completely abate in any of them. They were then treated successfully with infliximab. One patient had recurrence of symptoms and responded to repeat treatment with infliximab. Patients who develop immune-mediated colitis after administration of anti-CTLA-4 antibodies have previously been reported to respond to corticosteroids, but in our study, all required treatment with infliximab.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ICI-associated colitis is routinely treated with immunosuppressive therapy, including corticosteroids and/or agents targeting tumor necrosis factor alpha (TNF-alpha), all of which have significant side effects.”
From Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) · cites this paper as [8]
Citations
Cites
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · cited 2×
“Blockade of this receptor disinhibits T cells and can cause tumor regression and necrosis [9, 10].”
BackgroundKrummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · cited 3×
“, which found that the majority of patients who developed anti-CTLA-4induced immune mediated colitis responded to high doses of steroids [1].”
BackgroundSanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses
Chambers, C. A., Krummel, M. E., Boitel, B., Hurwitz, A., Sullivan, T. J., Fournier, S., Cassell, D., Brunner, M., & Allison, J. P. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00919.x · Cited by 211
Reuben, J. M., Lee, B., Li, C., Gomez‐Navarro, J., Bozon, V. A., Parker, C. A., Hernandez, I. M., Gutierrez, C., Lopez‐Berestein, G., & Camacho, L. H. (2006) · Cancer · doi:10.1002/cncr.21854 · Cited by 144 · cited 1×
“(New York)] and tremelimumab [formerly ticilimumab; Pfizer (New York)], are human monoclonal antibodies previously studied in phase III trials for the treatment of metastatic melanoma [1, 2].”
BackgroundActivity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
Keler, T., Halk, E., Vitale, L., O’Neill, T., Blanset, D., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T., Lonberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 134
Cited by
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
“However, in some situations, corticosteroids are insufficient and additional immunosuppressive agents, such as anti-tumor necrosis factor (anti-TNF ) monoclonal antibodies, are required.(5) In the pivotal randomized trial in which patients received ipilimumab alone or with a gp100 JOURNAL OF CLINICAL ONCOLOGY O R I G…”
BackgroundFecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740
Eggermont, A. M., Spatz, A., & Robert, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60802-8 · Cited by 548
Metadata
- Authors
- Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S.
- Affiliations
- University of Miami (US)
- Mount Sinai Medical Center (US)
- Corresponding author
- Barkin, J. S.
- Venue
- Digestive Diseases and Sciences
- Published
- 2008-12-23
- Volume
- 54
- Issue
- 11
- Pages
- 2538-2540
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2006091295
- Cited by
- 135
- References
- 11
- Citations by year
- 2026: 1 · 2024: 11 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 20 · 2017: 10 · 2016: 13 · 2015: 12 · 2014: 7 · 2013: 11 · 2012: 4
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- CTLA-4, anti-CTLA-4 antibody, immune-related colitis, infliximab, corticosteroids, metastatic melanoma, immune checkpoint inhibitors, drug-induced diarrhea, immune-related adverse events
- MeSH terms
- Infliximab, Ipilimumab, Adrenal Cortex Hormones, Aged, Antibodies, Monoclonal, Colitis, Female, Gastrointestinal Agents, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Antigens, CD, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.